Eisai High Potency API
Successful Pharma Facility Real Estate Transaction
Eisai Inc. retained PharmBioSource Realty, LLC as its exclusive real estate broker to market and sell its high potency API development and manufacturing facility in Andover, Massachusetts.
Eisai Inc. is a U.S. subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets therapeutic pharmaceutical products throughout the world. Eisai Inc., as part of its manufacturing site network consolidation plan, made the strategic decision to divest its 60,000 SF high potency small molecule API site.
The facility represented an excellent opportunity for a buyer to acquire a world-class development and manufacturing asset at a discount and with a significant reduction in time to market.
To assist Eisai with its goal of divesting its Andover, MA facility, PharmaBioSource Realty engaged the pharmaceutical industry to market and sell the facility to a strategic acquirer.
We utilized our real estate and technical expertise and extensive contacts within the pharmaceutical industry to identify a number of potential buyers for the Andover facility located on 26 acres 30 miles from Boston.
Services provided by the PharmaBioSource Realty team:
PharmaBioSource Realty, LLC identified Sarepta Therapeutics, a Cambridge, Massachusetts-based commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, as the acquirer. The transaction represented a significant value for Eisai and the entire deal was completed in just 7 months.